Analyst Recommendations for Valeant Pharmaceuticals in April

According to the terms of the agreement, Kaken Pharmaceutical granted an exclusive license to Valeant Pharmaceuticals for the development and commercialization of products containing KP-470 for the treatment of dermatological and rheumatological disorders in the United States, Canada, Western Europe, and Eastern Europe. In January 2018, Valeant Pharmaceuticals’ subsidiary Bausch & Lomb announced that the European Commission granted a CE mark for the Stellaris Elite vision enhancement system. Nineteen analysts are tracking Valeant Pharmaceuticals in April 2018.